London-listed pharma says it’s ready to recommend a newly revised higher offer from AbbVie, valuing the drugmaker at $90.53 per share.
London-listed pharma says it’s ready to recommend a newly revised higher offer from AbbVie, valuing the drugmaker at $90.53 per share.